Atrogi

Atrogi is a pioneering clinical-stage biotechnology company dedicated to advancing the treatment of metabolic diseases. It is developing first-in-class, insulin-independent therapies for type 2 diabetes and related metabolic conditions, including obesity and muscle-wasting disorders. The small molecule compound ATR-258, developed by the company, represents a revolutionary approach to type 2 diabetes treatment through its safety profile as a novel β2-adrenergic receptor agonist. ATR-258’s unique mechanism of action selectively modulates specific positive intracellular signaling pathways. This innovative method makes it possible to address the core issues of type 2 diabetes, effectively reversing it to preclinical levels of health as demonstrated in research.